A Stage-Based Approach to Therapy in Parkinson’s Disease
暂无分享,去创建一个
M. Onofrj | L. Bonanni | Astrid Thomas | Michela N. Vitale | S. Sensi | M. di Pietro | V. Di Stefano | F. Dono | M. Russo | C. Carrarini | M. Rispoli | Laura Ferri | F. Barbone
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] J. Jankovic,et al. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. , 2019, Parkinsonism & related disorders.
[3] R. Hauser,et al. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. , 2019, Parkinsonism & related disorders.
[4] E. Poliakoff,et al. Parkinson’s-adapted cognitive stimulation therapy: feasibility and acceptability in Lewy body spectrum disorders , 2019, Journal of Neurology.
[5] A. Lang,et al. Dystonia and Parkinson's disease: What is the relationship? , 2019, Neurobiology of Disease.
[6] M. Okun,et al. Emerging therapies in Parkinson disease — repurposed drugs and new approaches , 2019, Nature Reviews Neurology.
[7] J. Massano,et al. Contemporary Options for the Management of Motor Complications in Parkinson’s Disease: Updated Clinical Review , 2019, Drugs.
[8] W. Poewe,et al. Long‐term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open‐label extensions , 2019, European journal of neurology.
[9] K. Rejdak,et al. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease. , 2019, Annals of agricultural and environmental medicine : AAEM.
[10] A. Tafreshi,et al. Extended-Release Amantadine for Levodopa-Induced Dyskinesia , 2019, Expert review of neurotherapeutics.
[11] H. Park,et al. 1-O-Hexyl-2,3,5-Trimethylhydroquinone Ameliorates l-DOPA-Induced Cytotoxicity in PC12 Cells , 2019, Molecules.
[12] R. Pahwa,et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial , 2019, The Lancet Neurology.
[13] Daniel Weintraub,et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review , 2019, Movement disorders : official journal of the Movement Disorder Society.
[14] Sarah Diamond,et al. Multidisciplinary care for people with Parkinson’s disease: the new kids on the block! , 2019, Expert review of neurotherapeutics.
[15] R. Laureno,et al. Less Pulsatile Levodopa Therapy (6 Doses Daily) Is Associated with a Reduced Incidence of Dyskinesia , 2019, Journal of movement disorders.
[16] A. Sack,et al. Cognitive Stimulation for Individuals with Parkinson's Disease Dementia Living in Long-Term Care: Preliminary Data from a Randomized Crossover Pilot Study , 2018, Parkinson's disease.
[17] V. Kostic,et al. Chemical management of levodopa-induced dyskinesia in Parkinson’s disease patients , 2018, Expert opinion on pharmacotherapy.
[18] R. Hauser,et al. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease , 2018, Movement disorders clinical practice.
[19] J. C. Martínez‐Castrillo. Impulse control disorders in Parkinson’s disease: a hard-turning point , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[20] D. Pachito,et al. Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review , 2018, Journal of the Neurological Sciences.
[21] C. Sampaio,et al. International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[22] J. Assmus,et al. Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease , 2018, Acta neurologica Scandinavica.
[23] S. Federico,et al. A2A Adenosine Receptor Antagonists as Therapeutic Candidates: Are They Still an Interesting Challenge? , 2018, Mini reviews in medicinal chemistry.
[24] D. Truong,et al. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors , 2018, Journal of Neural Transmission.
[25] Jorik Nonnekes,et al. Freezing of gait: Promising avenues for future treatment. , 2018, Parkinsonism & related disorders.
[26] E. Deeks. Mirabegron: A Review in Overactive Bladder Syndrome , 2018, Drugs.
[27] S. Pallesen,et al. Impulse-Control Disorders in Parkinson’s Disease: A Meta-Analysis and Review of Case–Control Studies , 2018, Front. Neurol..
[28] Alberto J Espay,et al. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations , 2018, Movement disorders : official journal of the Movement Disorder Society.
[29] ▼ Safinamide for Parkinson’s disease , 2018, Drug and Therapeutics Bulletin.
[30] J. Ioannidis,et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis , 2018, The Lancet.
[31] L. Timmermann,et al. Management of constipation in patients with Parkinson’s disease , 2018, npj Parkinson's Disease.
[32] Jose-Alberto Palma,et al. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies , 2018, Movement disorders : official journal of the Movement Disorder Society.
[33] Jeffrey M. Hausdorff,et al. Multitarget transcranial direct current stimulation for freezing of gait in Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.
[34] A. Lang,et al. Caffeine as symptomatic treatment for Parkinson disease (Café-PD) , 2017, Neurology.
[35] C. Carroll,et al. Simvastatin as a Potential Disease-Modifying Therapy for Patients with Parkinson’s Disease: Rationale for Clinical Trial, and Current Progress , 2017, Journal of Parkinson's disease.
[36] Xia Shen,et al. Long-term effects of exercise and physical therapy in people with Parkinson disease , 2017, Nature Reviews Neurology.
[37] N. Greig,et al. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial , 2017, The Lancet.
[38] A. West,et al. LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model , 2017, Molecular therapy. Nucleic acids.
[39] C. Tanner,et al. ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial , 2017, JAMA neurology.
[40] Alan J. Thomas,et al. Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.
[41] D. Claassen,et al. Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease , 2017, Clinical Autonomic Research.
[42] John-Paul Taylor,et al. Psychosis in parkinsonism: an unorthodox approach , 2017, Neuropsychiatric disease and treatment.
[43] Giuseppe Di Giovanni,et al. Expanding the repertoire of L-DOPA’s actions: A comprehensive review of its functional neurochemistry , 2017, Progress in Neurobiology.
[44] G. Plazzi,et al. Sodium oxybate for idiopathic REM sleep behavior disorder: a report on two patients. , 2017, Sleep medicine.
[45] S. Fox,et al. Motor Complications of Dopaminergic Medications in Parkinson's Disease , 2017, Seminars in Neurology.
[46] H. Fernandez,et al. Dopamine agonist withdrawal syndrome: A comprehensive review , 2017, Journal of the Neurological Sciences.
[47] A. Cox,et al. Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin , 2017, Neuropsychiatric disease and treatment.
[48] J. Ferreira,et al. Opicapone for the treatment of Parkinson’s disease , 2017, Expert opinion on pharmacotherapy.
[49] W. Poewe,et al. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial , 2017, JAMA neurology.
[50] D. James Surmeier,et al. Selective neuronal vulnerability in Parkinson disease , 2017, Nature Reviews Neuroscience.
[51] C. Chapple,et al. Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia , 2017, Expert review of clinical pharmacology.
[52] M. Grundman,et al. First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers , 2016, Movement disorders : official journal of the Movement Disorder Society.
[53] S. Fox,et al. Novel Levodopa Formulations for Parkinson’s Disease , 2016, CNS Drugs.
[54] H. Fernandez,et al. Current Understanding of Psychosis in Parkinson’s Disease , 2016, Current Psychiatry Reports.
[55] J. Daneault,et al. The Effects of Physical Activity in Parkinson’s Disease: A Review , 2016, Journal of Parkinson's disease.
[56] P. Odin,et al. Continuous dopaminergic stimulation therapy for Parkinson's disease - recent advances. , 2016, Current opinion in neurology.
[57] J. Morgan,et al. Treating the Motor Symptoms of Parkinson Disease , 2016, Continuum.
[58] Bernhard Elsner,et al. Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease. , 2016, The Cochrane database of systematic reviews.
[59] S. Sveinbjornsdottir. The clinical symptoms of Parkinson's disease , 2016, Journal of neurochemistry.
[60] W. Poewe,et al. Mavoglurant in Parkinson's patients with l‐Dopa‐induced dyskinesias: Two randomized phase 2 studies , 2016, Movement disorders : official journal of the Movement Disorder Society.
[61] Alan J. Thomas,et al. Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations , 2016, Acta neuropathologica communications.
[62] S. Fox,et al. Nondopaminergic treatments for Parkinson's disease: current and future prospects. , 2016, Neurodegenerative disease management.
[63] T. Foltynie,et al. The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action. , 2016, Drug discovery today.
[64] R. Hauser,et al. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo‐controlled trial , 2016, Movement disorders : official journal of the Movement Disorder Society.
[65] J. Jankovic,et al. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia , 2016, Drugs.
[66] L. Bubacco,et al. Anti-Oxidants in Parkinson’s Disease Therapy: A Critical Point of View , 2016, Current neuropharmacology.
[67] Y Ben-Shlomo,et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.
[68] J. Borovac. Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology , 2016, The Yale journal of biology and medicine.
[69] T. van Laar,et al. Motor and non-motor outcomes of continuous apomorphine infusion in 125 Parkinson's disease patients. , 2016, Parkinsonism & related disorders.
[70] T. Warnecke,et al. Dysphagia in Parkinson’s Disease , 2016, Dysphagia.
[71] V. Fung,et al. Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients , 2016, Movement disorders : official journal of the Movement Disorder Society.
[72] S. Lorenzl,et al. A consensus review on the development of palliative care for patients with chronic and progressive neurological disease , 2016, European journal of neurology.
[73] M. Stacy,et al. Disease-Modifying Drugs in Parkinson’s Disease , 2015, Drugs.
[74] P. Martínez-Martín,et al. Double-blind Randomized Trial of t-DCS Versus Sham in Parkinson Patients With Mild Cognitive Impairment Receiving Cognitive Training , 2015, Brain Stimulation.
[75] Alice Nieuwboer,et al. Transcranial direct current stimulation in Parkinson's disease: Neurophysiological mechanisms and behavioral effects , 2015, Neuroscience & Biobehavioral Reviews.
[76] G. Deuschl,et al. MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[77] Günther Deuschl,et al. MDS research criteria for prodromal Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[78] Klaus Seppi,et al. Probable RBD and association with neurodegenerative disease markers: A population‐based study , 2015, Movement disorders : official journal of the Movement Disorder Society.
[79] Y. Kim,et al. Efficacy of cumulative high-frequency rTMS on freezing of gait in Parkinson’s disease , 2015, Restorative neurology and neuroscience.
[80] O. Tysnes,et al. Development of excessive daytime sleepiness in early Parkinson disease , 2015, Neurology.
[81] M. Onofrj,et al. Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism , 2015, Medicine.
[82] Cynthia Fox,et al. Evidence-based treatment of voice and speech disorders in Parkinson disease , 2015, Current opinion in otolaryngology & head and neck surgery.
[83] D. Weintraub,et al. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo‐controlled study , 2015, Movement disorders : official journal of the Movement Disorder Society.
[84] S. Kusunoki,et al. Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson’s Disease , 2015, Dysphagia.
[85] A. Rana,et al. Parkinson’s disease: a review of non-motor symptoms , 2015, Expert review of neurotherapeutics.
[86] L. Schneider,et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. , 2015, JAMA psychiatry.
[87] M. Onofrj,et al. Dopamine Transporter Single-Photon Emission Computerized Tomography Supports Diagnosis of Akinetic Crisis of Parkinsonism and of Neuroleptic Malignant Syndrome , 2015, Medicine.
[88] E. Tolosa,et al. Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD , 2015, Neurology.
[89] Tanya Simuni,et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. , 2015, JAMA.
[90] A. Björklund,et al. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study , 2015, Brain : a journal of neurology.
[91] M. Tagliati,et al. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson's disease. , 2015, Parkinsonism & related disorders.
[92] A. Lang,et al. Behavioral effects of levodopa , 2015, Movement disorders : official journal of the Movement Disorder Society.
[93] P. Dasgupta,et al. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3‐adrenoceptor agonist (Mirabegron) for overactive bladder (OAB) , 2015, BJU international.
[94] Susan H Fox,et al. Clinical spectrum of levodopa‐induced complications , 2015, Movement disorders : official journal of the Movement Disorder Society.
[95] M. Ziman,et al. A Systematic Review and Meta-Analysis of Strength Training in Individuals With Multiple Sclerosis Or Parkinson Disease , 2015, Medicine.
[96] P. Lewitt,et al. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics , 2015, Movement disorders : official journal of the Movement Disorder Society.
[97] R. Freeman,et al. Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa , 2014, Hypertension.
[98] A. Hohler,et al. Management of orthostatic hypotension in patients with Parkinson's disease , 2014, Practical Neurology.
[99] D. Jennings,et al. Imaging prodromal Parkinson disease , 2014, Neurology.
[100] C. Counsell,et al. Mortality in Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[101] J. Crippa,et al. Cannabidiol can improve complex sleep‐related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: a case series , 2014, Journal of clinical pharmacy and therapeutics.
[102] M. Tagliati,et al. Cholinesterase inhibitors for Parkinson's disease: a systematic review and meta-analysis , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[103] Matthew Rizzo,et al. Phase I/II randomized trial of aerobic exercise in Parkinson disease in a community setting , 2014, Neurology.
[104] Filippo Brighina,et al. Transcranial direct current stimulation for treatment of freezing of gait: A cross‐over study , 2014, Movement disorders : official journal of the Movement Disorder Society.
[105] T. Dawson,et al. The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease , 2014, Scientific Reports.
[106] Stephanie D. Wilson,et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. , 2014, JAMA neurology.
[107] A. Lang,et al. Pharmacological treatment of Parkinson disease: a review. , 2014, JAMA.
[108] T. Foltynie,et al. Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells , 2014, Brain : a journal of neurology.
[109] J. Cummings,et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial , 2014, The Lancet.
[110] K. Kieburtz,et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study , 2014, The Lancet Neurology.
[111] L. Marsh,et al. Anxiety in Parkinson’s disease: identification and management , 2014, Therapeutic advances in neurological disorders.
[112] P. Stanzione,et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations , 2013, Movement disorders : official journal of the Movement Disorder Society.
[113] L. Defebvre,et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial , 2013, Journal of Neurology, Neurosurgery & Psychiatry.
[114] Tejas Sankar,et al. Deep brain stimulation for Parkinson's disease and other movement disorders. , 2013, Current opinion in neurology.
[115] E. Hirsch,et al. Gait Disorders in Parkinsonian Monkeys with Pedunculopontine Nucleus Lesions: A Tale of Two Systems , 2013, The Journal of Neuroscience.
[116] C. Plewnia,et al. Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial , 2013, Brain : a journal of neurology.
[117] J. Assmus,et al. Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease , 2013, Acta neurologica Scandinavica.
[118] Y. Mizuno,et al. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson’s disease , 2013, Movement disorders : official journal of the Movement Disorder Society.
[119] B. Boeve,et al. Treatment outcomes in REM sleep behavior disorder. , 2013, Sleep medicine.
[120] G. Deuschl,et al. Neurostimulation for Parkinson's disease with early motor complications. , 2013, The New England journal of medicine.
[121] John D Sorkin,et al. Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease. , 2013, JAMA neurology.
[122] M. Matsuura,et al. Factors associated with the effect of pramipexole on symptoms of idiopathic REM sleep behavior disorder. , 2013, Parkinsonism & related disorders.
[123] A. Berardelli,et al. Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease , 2013, European journal of neurology.
[124] T. Paparrigopoulos,et al. Agomelatine may improve REM sleep behavior disorder symptoms. , 2012, Journal of clinical psychopharmacology.
[125] A. Strafella,et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[126] Richard L. Doty,et al. Olfactory dysfunction in Parkinson disease , 2012, Nature Reviews Neurology.
[127] Antonio Daniele,et al. Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation , 2012, The Lancet Neurology.
[128] W. Oertel,et al. Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.
[129] M. Gundeti,et al. Urinary tract dysfunction in Parkinson’s disease: a review , 2012, International Urology and Nephrology.
[130] I. Maidment,et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. , 2012, The Cochrane database of systematic reviews.
[131] G. P. Herbison,et al. Which anticholinergic drug for overactive bladder symptoms in adults. , 2012, The Cochrane database of systematic reviews.
[132] B. Abler,et al. Neural reward processing under dopamine agonists: Imaging , 2011, Journal of the Neurological Sciences.
[133] R. Sakakibara,et al. Levodopa ameliorated anorectal constipation in de novo Parkinson's disease: The QL-GAT study. , 2011, Parkinsonism & related disorders.
[134] M. Mark,et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. , 2011, The American journal of psychiatry.
[135] W. Poewe,et al. The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[136] C. Adler,et al. MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD‐MCI , 2011, Movement disorders : official journal of the Movement Disorder Society.
[137] G. Yener,et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double‐blind, placebo‐controlled, multicenter study , 2011, Movement disorders : official journal of the Movement Disorder Society.
[138] P. Kempster,et al. A randomized, double‐blind, placebo‐controlled trial of levetiracetam for dyskinesia in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[139] W. Ondo,et al. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. , 2011, Parkinsonism & related disorders.
[140] G. Fink,et al. Akinetic‐rigid and tremor‐dominant Parkinson's disease patients show different patterns of FP‐CIT Single photon emission computed tomography , 2011, Movement disorders : official journal of the Movement Disorder Society.
[141] S. Konitsiotis,et al. Levetiracetam for the management of levodopa‐induced dyskinesias in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[142] A. Albanese,et al. EFNS guidelines on diagnosis and treatment of primary dystonias , 2011, European journal of neurology.
[143] K. Hisanaga,et al. Amantadine for Dyskinesias in Parkinson's Disease: A Randomized Controlled Trial , 2010, PloS one.
[144] D. Kunz,et al. A two‐part, double‐blind, placebo‐controlled trial of exogenous melatonin in REM sleep behaviour disorder , 2010, Journal of sleep research.
[145] P. Calabresi,et al. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap , 2010, The Lancet Neurology.
[146] F. Horak,et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease , 2010, Neurology.
[147] Roy W Jones,et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial , 2010, The Lancet Neurology.
[148] E. Londos,et al. The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia , 2010, International journal of geriatric psychiatry.
[149] T. Welty,et al. Management of hallucinations and psychosis in Parkinson's disease. , 2010, The American journal of geriatric pharmacotherapy.
[150] Grant D. Huang,et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. , 2010, The New England journal of medicine.
[151] P. Barone,et al. Neurotransmission in Parkinson’s disease: beyond dopamine , 2010, European journal of neurology.
[152] J. Friedman,et al. Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis , 2010, Neuropsychopharmacology.
[153] S. Auerbach,et al. Best practice guide for the treatment of REM sleep behavior disorder (RBD). , 2010, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.
[154] Werner Poewe,et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.
[155] A. Schapira,et al. Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis , 2009, European journal of neurology.
[156] B. Bloem,et al. Multidisciplinary care for patients with Parkinson's disease. , 2009, Parkinsonism & related disorders.
[157] A. Antonini,et al. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. , 2009, Parkinsonism & related disorders.
[158] D. Maraganore,et al. Medical records documentation of constipation preceding Parkinson disease , 2009, Neurology.
[159] R. Hauser,et al. Review: Improving symptom control in early Parkinson’s disease , 2009, Therapeutic advances in neurological disorders.
[160] J. Shneerson. Successful Treatment of REM Sleep Behavior Disorder With Sodium Oxybate , 2009, Clinical neuropharmacology.
[161] M. Dafotakis,et al. Transdermal dopaminergic stimulation with rotigotine in Parkinsonian akinetic crisis , 2009, Journal of Clinical Neuroscience.
[162] E. Tolosa,et al. Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease. , 2008, Sleep.
[163] R. Postuma,et al. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder , 2008, Movement disorders : official journal of the Movement Disorder Society.
[164] Pablo Mir,et al. Efficacy of long‐term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study , 2008, Movement disorders : official journal of the Movement Disorder Society.
[165] C. Davie. A review of Parkinson's disease. , 2008, British medical bulletin.
[166] J. Ferreira,et al. Dopamine agonist therapy in early Parkinson's disease. , 2008, The Cochrane database of systematic reviews.
[167] J. Jankovic. Parkinson’s disease: clinical features and diagnosis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[168] R. Sakakibara,et al. Bladder and bowel dysfunction in Parkinson’s disease , 2008, Journal of Neural Transmission.
[169] T. Anderson,et al. A Pilot Study of Respiration and Swallowing Integration in Parkinson’s Disease: “On” and “Off” Levodopa , 2008, Dysphagia.
[170] M W Mahowald,et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. , 2007, Brain : a journal of neurology.
[171] W. Poewe. Depression in Parkinson's disease , 2007, Journal of Neurology.
[172] K. Gwinn‐Hardy,et al. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group , 2007, Movement disorders : official journal of the Movement Disorder Society.
[173] H. Braak,et al. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons , 2007, Acta Neuropathologica.
[174] A. Antonini,et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.
[175] D. Aarsland,et al. Insomnia in Parkinson’s disease: frequency and progression over time , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[176] K. Fuxe,et al. Targeting adenosine A2A receptors in Parkinson's disease , 2006, Trends in Neurosciences.
[177] J. Jankovic,et al. Treatment of dystonia , 2006, The Lancet Neurology.
[178] J. Langston,et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP‐treated primates , 2006, Journal of neurochemistry.
[179] G. Deuschl,et al. A randomized trial of deep-brain stimulation for Parkinson's disease. , 2006, The New England journal of medicine.
[180] José Luis Molinuevo,et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study , 2006, The Lancet Neurology.
[181] C. Fowler,et al. Bladder dysfunction in Parkinsonism: Mechanisms, prevalence, symptoms, and management , 2006, Movement disorders : official journal of the Movement Disorder Society.
[182] A. Lieberman. Depression in Parkinson's disease – a review , 2006, Acta neurologica Scandinavica.
[183] M. Onofrj,et al. Akinetic crisis, acute akinesia, neuroleptic malignant‐like syndrome, Parkinsonism–hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal , 2005, Movement disorders : official journal of the Movement Disorder Society.
[184] Jack J. Chen,et al. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. , 2005, Clinical therapeutics.
[185] Esra Kılıç,et al. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder , 2005, Clinical Neurology and Neurosurgery.
[186] Dag Aarsland,et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. , 2005, The Journal of clinical psychiatry.
[187] M. Onofrj,et al. Acute akinesia in Parkinson disease , 2005, Neurology.
[188] W Poewe,et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial , 2005, The Lancet.
[189] N. Borges. Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy , 2005, Expert opinion on drug safety.
[190] R. Miall,et al. Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey , 2004, Neuroreport.
[191] M. Onofrj,et al. Improvement of motor function in early Parkinson disease by safinamide , 2004, Neurology.
[192] Richard Gray,et al. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients , 2004, BMJ : British Medical Journal.
[193] E. Wolters,et al. Cognitive dysfunction and dementia in Parkinson’s disease , 2004, Journal of Neural Transmission.
[194] R. Dewey,et al. Management of motor complications in Parkinson’s disease , 2004, Neurology.
[195] S. Factor,et al. Rapid treatment of “off” episodes , 2004, Neurology.
[196] J. Obeso,et al. The origin of motor fluctuations in Parkinson’s disease , 2004, Neurology.
[197] J. Montplaisir,et al. The effects of pramipexole in REM sleep behavior disorder , 2003, Neurology.
[198] Alan J. Thomas,et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia , 2003, International journal of geriatric psychiatry.
[199] K. Jellinger. The association of incident dementia with mortality in PD , 2003, Neurology.
[200] B. Boeve,et al. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. , 2003, Sleep medicine.
[201] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[202] C. Clarke,et al. Amantadine in Parkinson's disease. , 2003, Lancet.
[203] K. Marder,et al. The association of incident dementia with mortality in PD , 2002, Neurology.
[204] R. Brown,et al. Apathy in Parkinson’s disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[205] G. Halliday,et al. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. , 2002, Brain : a journal of neurology.
[206] D. Garcia-Borreguero,et al. Decreased phasic EMG activity during rapid eye movement sleep in treatment‐naïve Parkinson's disease: Effects of treatment with levodopa and progression of illness , 2002, Movement disorders : official journal of the Movement Disorder Society.
[207] S. Gilbody,et al. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials , 2002, Schizophrenia Research.
[208] N. Uchimura,et al. Melatonin therapy for REM sleep behavior disorder , 2001 .
[209] L. Metman,et al. Intravenous amantadine improves levadopa‐induced dyskinesias: An acute double‐blind placebo‐controlled study , 2001, Movement disorders : official journal of the Movement Disorder Society.
[210] K. Walsh,et al. Parkinson's disease and anxiety , 2001, Postgraduate medical journal.
[211] M. Schiess,et al. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study. , 2000, Neurology.
[212] C. Warren Olanow,et al. Tolcapone and Hepatotoxic Effects , 2000 .
[213] B. Boeve,et al. Rapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 cases. , 2000, Brain : a journal of neurology.
[214] R. Llinás,et al. Thalamocortical dysrhythmia: A neurological and neuropsychiatric syndrome characterized by magnetoencephalography. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[215] E. Tolosa,et al. Immediate-release and controlled-release carbidopa/levodopa in PD , 1999, Neurology.
[216] S Fahn,et al. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA. , 1999, Archives of neurology.
[217] R. Roth,et al. Comparison of Neurotoxicity following Repeated Administration of L-Dopa, D-Dopa, and Dopamine to Embryonic Mesencephalic Dopamine Neurons in Cultures Derived from Fisher 344 and Sprague-Dawley Donors , 1997 .
[218] S. Daniel,et al. Olfactory dysfunction in Parkinson's disease. , 1997, Journal of neurology, neurosurgery, and psychiatry.
[219] A. Brzezinski. Melatonin in humans. , 1997, The New England journal of medicine.
[220] R Kieburtz,et al. Effect of lazabemide on the progression of disability in early Parkinson's disease , 1996, Annals of neurology.
[221] M. Mahowald,et al. Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. , 1996, The American journal of medicine.
[222] J. Hubble,et al. Pramipexole in patients with early Parkinson's disease. , 1995, Clinical neuropharmacology.
[223] E. Melamed,et al. Psychosis in advanced Parkinson's disease , 1995, Neurology.
[224] C. Waters,et al. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.
[225] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[226] M. Mahowald,et al. REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature , 1993 .
[227] R. Palluk,et al. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans , 1992, Clinical pharmacology and therapeutics.
[228] R. Doty,et al. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[229] J. Kornhuber,et al. Pharmacotoxic psychosis after memantine in Parkinson's disease , 1991, The Lancet.
[230] E. Perry,et al. Evidence of a Monoaminergic‐Cholinergic Imbalance Related to Visual Hallucinations in Lewy Body Dementia , 1990, Journal of neurochemistry.
[231] J. Nutt,et al. Peripheral pharmacokinetics of apomorphine in humans , 1989, Annals of neurology.
[232] R. McCarley,et al. Cholinergic activation of medial pontine reticular formation neurons in vitro , 1989, Brain Research.
[233] M Onofrj,et al. Alterations in event-related potentials (ERPs) of MPTP-treated monkeys. , 1988, Electroencephalography and clinical neurophysiology.
[234] E. Tolosa,et al. Parkinson's disease with depression , 1986, Neurology.
[235] A. Morrison,et al. Different behaviors during paradoxical sleep without atonia depend on pontine lesion site , 1982, Brain Research.
[236] H. Pakkenberg,et al. PARKINSON'S DISEASE TREATED WITH SINEMET OR MADOPAR , 1976 .
[237] M. Hoehn,et al. Parkinsonism , 1967, Neurology.
[238] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[239] J. Friedman,et al. Cognitive Effects of Rasagiline in Mild-to-Moderate Stage Parkinson's Disease Without Dementia. , 2017, The Journal of neuropsychiatry and clinical neurosciences.
[240] J. Kulisevsky,et al. Apathy in Parkinson's Disease. , 2017, International review of neurobiology.
[241] K. Nakashima,et al. Beneficial Effects of Ramelteon on Rapid Eye Movement Sleep Behavior Disorder Associated with Parkinson's Disease - Results of a Multicenter Open Trial. , 2016, Internal medicine.
[242] Á. Sesar,et al. Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study. , 2016, Journal of Parkinson's disease.
[243] M. Zigmond,et al. Exercise: is it a neuroprotective and if so, how does it work? , 2014, Parkinsonism & related disorders.
[244] Suneil K. Kalia,et al. Parkinson hastalığı ve diğer hareket bozuklukları için derin beyin stimülasyonu , 2013 .
[245] K. Chaudhuri,et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non motor effect. , 2011, Journal of Parkinson's disease.
[246] M. Nirenberg,et al. Dopamine agonist withdrawal syndrome in Parkinson disease. , 2010, Archives of neurology.
[247] R. Zweig,et al. Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. , 2010, Parkinsonism & related disorders.
[248] R. Trosch,et al. Intermittent Subcutaneous Apomorphine Therapy for ‘Off’ Episodes in Parkinson’s Disease , 2008, CNS drugs.
[249] S. Papapetropoulos. A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease , 2008 .
[250] M. Onofrj,et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. , 2004, Journal of neurology, neurosurgery, and psychiatry.
[251] Y. Ben-Shlomo,et al. Speech and language therapy for dysarthria in Parkinson's disease. , 2001, The Cochrane database of systematic reviews.
[252] P. Foley. The L-DOPA story revisited. Further surprises to be expected? , 2000, Journal of neural transmission. Supplementum.
[253] D. Rye. Contributions of the pedunculopontine region to normal and altered REM sleep. , 1997, Sleep.
[254] W. Danielczyk. Twenty-five years of amantadine therapy in Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.
[255] G. Pezzoli,et al. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study , 1994, Movement disorders : official journal of the Movement Disorder Society.
[256] Mahowald,et al. Symposium: Normal and abnormal REM sleep regulation: REM sleep behaviour disorder: an update on a series of 96 patients and a review of the world literature. , 1993, Journal of sleep research.
[257] A. Hughes,et al. Subcutaneous apomorphine in parkinson's disease: Response to chronic administration for up to five years , 1993, Movement disorders : official journal of the Movement Disorder Society.
[258] R. Kurlan,et al. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. , 1992, The Journal of neuropsychiatry and clinical neurosciences.
[259] E. Quigley,et al. Gastrointestinal symptoms in Parkinson's disease , 1991, Movement disorders : official journal of the Movement Disorder Society.
[260] DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.
[261] M. Ghilardi,et al. Systemic 1-methyl,4-phenyl,1-2-3-6-tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. , 1988, Life sciences.
[262] H. Pakkenberg,et al. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial. , 1976, Acta Neurologica Scandinavica.